文献速递肿瘤 PET/CT骨显像与常规 SPECT

乳腺癌手术切除后[18F]FDG PET/CT骨髓摄取预测远处复发

[18F]FDG uptake of bone marrow on PET/CT for predicting distant recurrence in breast cancer patients after surgical resection.
PubMed 文献 · EJNMMI Res · 2020-06-30

该回顾性研究评估345例乳腺癌患者治疗前[18F]FDG PET/CT骨髓与肝脏摄取比值(BLR)及原发肿瘤代谢参数对复发的预测价值,中位随访48.7个月,36例(10.4%)复发。多因素分析显示BLR与无复发生存(RFS)和远处无复发生存(distant RFS)均显著相关(P=0.001)。BLR与肿瘤总病灶糖酵解(TLG)联合可对远处复发风险进行分层。

要点

  • 治疗前[18F]FDG PET/CT的BLR是乳腺癌RFS和distant RFS的显著预测因子。
  • BLR≥0.91且TLG≥9.64 g的患者远处复发率为40.7%,BLR<0.91且TLG<9.64 g者仅0.5%。
  • BLR与T分期、血清炎症标志物及复发模式显著相关(P<0.05)。

核心结论

  • 治疗前[18F]FDG PET/CT的BLR是乳腺癌患者RFS和distant RFS的显著预测因子。
  • 联合骨髓[18F]FDG摄取与乳腺癌体积PET/CT指数可对远处复发风险进行分层。

研究设计与样本

  • 回顾性评估345例乳腺癌患者治疗前[18F]FDG PET/CT图像。
  • 测量原发乳腺癌最大标准化摄取值、代谢肿瘤体积和TLG,以及骨髓与肝脏摄取比值(BLR)。
  • 采用Cox比例风险回归模型评估参数对RFS和distant RFS的预测潜力。
  • Kaplan-Meier分析中BLR和TLG的特定截断值由最大卡方法确定。

主要发现

  • 中位随访48.7个月,随访期间36例(10.4%)患者发生癌症复发。
  • BLR与T分期、血清炎症标志物和复发模式显著相关(P<0.05)。
  • 高BLR和高TLG患者RFS和distant RFS均差于低BLR和低TLG患者。
  • 多因素分析中,调整T分期、雌激素受体状态和TLG后,BLR与RFS和distant RFS均显著相关(两者P=0.001)。
  • TLG<9.64 g且BLR<0.91的患者中仅0.5%发生远处复发;TLG≥9.64 g且BLR≥0.91的患者远处复发率为40.7%。

关键数值与推荐

  • BLR截断值为0.91,TLG截断值为9.64 g,由最大卡方法确定。
  • BLR与RFS和distant RFS关联的多因素分析P值均为0.001。
  • TLG<9.64 g且BLR<0.91组远处复发率0.5%;TLG≥9.64 g且BLR≥0.91组远处复发率40.7%。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The objective of this study was to investigate the prognostic value of 2-Deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake of bone marrow (BM) and metabolic parameters of primary tumor on positron emission tomography/computed tomography (PET/CT) for predicting distant recurrence in patients with breast cancer. METHODS: Pretreatment [18F]FDG PET/CT images of 345 breast cancer patients were retrospectively evaluated. Maximum standardized uptake value, metabolic tumor volume, and total lesion glycolysis (TLG) of primary breast cancer and bone marrow-to-liver uptake ratio (BLR) on PET/CT were measured. A Cox proportional hazard regression model was used to evaluate the prognostic potential of parameters for predicting recurrence-free survival (RFS) and distant RFS. For Kaplan-Meier analysis, the specific cutoff values pf BLR and TLG were determined by the maximal chi-square method. RESULTS: The median follow-up duration of the enrolled patients was 48.7 months, and during follow-up, 36 patients (10.4%) experienced the cancer recurrence. BLR was significantly correlated with T stage, serum inflammatory markers, and recurrence pattern (p < 0.05). Patients with high BLR and TLG showed worse RFS and distant RFS than those with low BLR and TLG. On multivariate analysis, BLR was significantly associated with both RFS and distant RFS after adjusting for T stage, estrogen receptor status, and TLG (p = 0.001 for both). Only 0.5% of patients with TLG < 9.64 g and BLR < 0.91 experienced distant recurrence. However, patients with TLG ≥ 9.64 g and BLR ≥ 0.91 had a distant recurrence rate of 40.7%. CONCLUSIONS: BLR on pretreatment [18F]FDG PET/CT were significant predictors for RFS and distant RFS in patients with breast cancer. By combining [18F]FDG uptake of BM and volumetric PET/CT index of breast cancer, the risk of distant recurrence could be stratified.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Lee JW, Kim SY, Han SW, et al. [18F]FDG uptake of bone marrow on PET/CT for predicting distant recurrence in breast cancer patients after surgical resection. EJNMMI Res. 2020. PMID: 32607957. doi:10.1186/s13550-020-00660-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。